Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801436 | 0.77 | USP2 (0.48) | USP2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL89770 | 0.74 | USP2 (0.47) | USP2ALDH1A1LMNAALOX15SMN1; SMN2 | |
| SCHEMBL2289352 | 0.71 | CYP1A2 (0.34) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL261687 | 0.68 | PTGS1 (0.39) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL56694 | 0.67 | USP2 (0.50) | USP2ALDH1A1LMNAALOX15SMN1; SMN2 | |
| SCHEMBL1862014 | 0.67 | S1PR1 (0.44) | — | |
| SCHEMBL1857766 | 0.67 | S1PR1 (0.44) | — | |
| SCHEMBL1857863 | 0.67 | S1PR1 (0.40) | — | |
| SCHEMBL1857451 | 0.66 | S1PR1 (0.41) | — | |
| SCHEMBL4474280 | 0.65 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951794-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-31 | — | — | US | disclosed |
| US-20100075946-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-25 | — | — | US | disclosed |
| EP-1896446-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137019-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075946-A1 | NOVEL THIOPHENE DERIVATIVES | TPMT, TSLP, NFATC1 | USP2 4194/4885ALDH1A1 2314/4885LMNA 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.